KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $206000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $206000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $206000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $206000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $206000.0 at Supernus Pharmaceuticals, down from $11.4 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $57.4 million in Q3 2022, with the low at $206000.0 in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $18.2 million, with a median of $8.7 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities tumbled 92.02% in 2024, then soared 1013.63% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $35.6 million in 2021, then tumbled by 75.61% to $8.7 million in 2022, then dropped by 26.12% to $6.4 million in 2023, then rose by 14.45% to $7.4 million in 2024, then crashed by 97.2% to $206000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $206000.0, $11.4 million, and $7.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.